- Scribe Therapeutics achieves a major milestone in its collaboration with Prevail Therapeutics, part of Eli Lilly's gene therapy division.
- Joint presentation on self-inactivating AAV technology for neurological and neuromuscular disorders at the ASGCT Annual Meeting.
- Scribe is eligible for over $1.5 billion in milestone payments from its collaboration with Prevail Therapeutics.
Scribe Therapeutics Inc., a leader in genetic medicines employing CRISPR technology, has announced the achievement of a significant milestone in its collaboration with Prevail Therapeutics, a subsidiary of Eli Lilly (LLY, Financial). This milestone is part of their ongoing efforts to develop in vivo CRISPR-based therapeutics targeting neurological and neuromuscular disorders. The achievement signifies Scribe's second partnership milestone within 2025.
The companies will jointly present their preclinical data on self-inactivating AAV (siXAAV) technology at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The presentation, titled "Self-Targeting CRISPR-CasX-Editor AAV Vectors Enable Potent and Controllable On-target Editing in the Murine CNS," is scheduled for May 15, 2025, in New Orleans.
Dr. Benjamin Oakes, CEO of Scribe, expressed his excitement about the progress made with Prevail and Lilly's teams, highlighting the potential leap towards safer and more effective in vivo genetic medicines for neurodegenerative disorders. Scribe utilizes its proprietary CRISPR by Designâ„¢ approach, optimizing CRISPR platforms like the X-Editor (XE) technology.
Scribe's collaboration with Prevail, announced in 2023, positions the company to receive over $1.5 billion in milestone payments and low-double-digit royalties, reflecting the powerful synergy between Scribe's CRISPR innovation and Prevail's focus on neurological and neuromuscular disorders.
